Acute left ventricular insufficiency in a Burkitt Lymphoma patient with myocardial involvement and extensive local tumor cell lysis: a case report.
Acute cardiac insufficiency
Burkitt Lymphoma
Cardiac neoplasms
Case report
Myocardial lymphoma involvement
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
04 02 2022
04 02 2022
Historique:
received:
25
11
2021
accepted:
27
01
2022
entrez:
5
2
2022
pubmed:
6
2
2022
medline:
1
3
2022
Statut:
epublish
Résumé
Burkitt lymphoma (BL) is a rare disease with the sporadic variant accounting for less than 1% of adult non-Hodgkin lymphomas. BL usually presents with an abdominal bulk, but extranodal disease affecting the bone marrow and central nervous system is common. Cardiac manifestations, however, are exceedingly rare, with less than 30 cases reported in the literature. We report on a 54-year-old male patient with a six week-long history of paranasal sinus swelling, fatigue and dyspnea on exertion. Stage IV sporadic BL with extensive lymphonodal and cardiovascular involvement was diagnosed. Manifestations included supra- and infradiaphragmatic lymphadenopathy as well as infiltration of the aortic root, the pericardium, the right atrium and the right ventricle. EBV-reactivation was detected, which is uncommon in the sporadic subtype. After initial full-dose chemotherapy with very good BL control, the patient developed acute, but fully reversible cardiac insufficiency. Myocardial lymphoma involvement receded completely during the following two therapy cycles, while cardiac function periodically deteriorated shortly after chemotherapy administration and quickly recovered thereafter. Interestingly, the decline in cardiac function lessened with decreasing myocardial lymphoma manifestation. Once the cardiovascular BL infiltration was resolved, cardiac function remained stable throughout further treatment. Following seven cycles of chemotherapy and mediastinal radiation, the patient is now in continued complete remission. Although rare, cardiac involvement in BL can quickly become life-threatening due to rapid lymphoma doubling time and should therefore be considered at initial diagnosis. This case suggests an association between myocardial infiltration, chemotherapy associated tumor cell lysis and transient deterioration of cardiac function until the damage caused by the underlying lymphoma could be restored. While additional studies are needed to further elucidate the mechanisms of acute cardiac insufficiency due to lymphoma lysis in the infiltrated structures, prompt BL control and full recovery of the patient supports courageous treatment start despite extensive cardiovascular involvement.
Sections du résumé
BACKGROUND
Burkitt lymphoma (BL) is a rare disease with the sporadic variant accounting for less than 1% of adult non-Hodgkin lymphomas. BL usually presents with an abdominal bulk, but extranodal disease affecting the bone marrow and central nervous system is common. Cardiac manifestations, however, are exceedingly rare, with less than 30 cases reported in the literature.
CASE PRESENTATION
We report on a 54-year-old male patient with a six week-long history of paranasal sinus swelling, fatigue and dyspnea on exertion. Stage IV sporadic BL with extensive lymphonodal and cardiovascular involvement was diagnosed. Manifestations included supra- and infradiaphragmatic lymphadenopathy as well as infiltration of the aortic root, the pericardium, the right atrium and the right ventricle. EBV-reactivation was detected, which is uncommon in the sporadic subtype. After initial full-dose chemotherapy with very good BL control, the patient developed acute, but fully reversible cardiac insufficiency. Myocardial lymphoma involvement receded completely during the following two therapy cycles, while cardiac function periodically deteriorated shortly after chemotherapy administration and quickly recovered thereafter. Interestingly, the decline in cardiac function lessened with decreasing myocardial lymphoma manifestation. Once the cardiovascular BL infiltration was resolved, cardiac function remained stable throughout further treatment. Following seven cycles of chemotherapy and mediastinal radiation, the patient is now in continued complete remission.
CONCLUSIONS
Although rare, cardiac involvement in BL can quickly become life-threatening due to rapid lymphoma doubling time and should therefore be considered at initial diagnosis. This case suggests an association between myocardial infiltration, chemotherapy associated tumor cell lysis and transient deterioration of cardiac function until the damage caused by the underlying lymphoma could be restored. While additional studies are needed to further elucidate the mechanisms of acute cardiac insufficiency due to lymphoma lysis in the infiltrated structures, prompt BL control and full recovery of the patient supports courageous treatment start despite extensive cardiovascular involvement.
Identifiants
pubmed: 35120455
doi: 10.1186/s12872-022-02480-5
pii: 10.1186/s12872-022-02480-5
pmc: PMC8815241
doi:
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
31Informations de copyright
© 2022. The Author(s).
Références
Case Rep Hematol. 2014;2014:687598
pubmed: 25431699
J Pediatr Hematol Oncol. 2019 Apr;41(3):e197-e200
pubmed: 30299348
Pediatr Blood Cancer. 2009 Sep;53(3):366-70
pubmed: 19434731
J Cardiothorac Surg. 2007 Jul 05;2:30
pubmed: 17615068
Am J Cardiol. 1968 Jul;22(1):85-107
pubmed: 4873149
Am J Case Rep. 2016 Aug 03;17:553-8
pubmed: 27484990
BMJ Case Rep. 2017 Jul 18;2017:
pubmed: 28720604
Cancer. 1982 Mar 1;49(5):944-51
pubmed: 7037154
Biomed Pharmacother. 2018 Nov;107:989-996
pubmed: 30257411
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Am J Pathol. 1984 Oct;117(1):140-53
pubmed: 6486242
Blood. 2006 Jan 1;107(1):265-76
pubmed: 16150940
Drug Saf. 2000 Apr;22(4):263-302
pubmed: 10789823
Int J Immunopharmacol. 1987;9(3):355-61
pubmed: 3497116
Acta Clin Belg. 2017 Jun;72(3):198-200
pubmed: 27355914
Lancet Oncol. 2017 Aug;18(8):e445-e456
pubmed: 28759384
J Clin Pathol. 2007 Dec;60(12):1397-402
pubmed: 18042696
Blood. 2014 Dec 18;124(26):3870-9
pubmed: 25359988
Radiol Case Rep. 2017 Jan 05;12(1):185-190
pubmed: 28228907
Life Sci. 2019 Feb 1;218:112-131
pubmed: 30552952
Clin Lymphoma Myeloma. 2008 Aug;8(4):249-52
pubmed: 18765314
Eur J Haematol. 2016 Nov;97(5):445-452
pubmed: 26935129
Cancer Res. 1986 Jan;46(1):54-60
pubmed: 3484381
Blood. 2004 Nov 15;104(10):3009-20
pubmed: 15265787